- Open Access
Adverse drug reactions monitoring: prospects and impending challenges for pharmacovigilance
SpringerPlus volume 3, Article number: 695 (2014)
Pharmacovigilance plays a consequential role in the surveillance of adverse drug reactions, which is provoked by the drugs used to cure diseases. Adverse drug reactions (ADRs) produce detrimental or undesirable effects to the body after administration of drugs. It has been reported that the number of patients dying because of contrary effects of drugs per year increased upto 2.6-fold. Moreover, rates of hospitalization of patients are increasing owing to adverse effects of drugs. Thus, it becomes challengeable for physician, health care providers, WHO and pharmaceutical industries to resolve the associated problem of ADRs. During the clinical trial of a novel drug, it is prominent to explore the dependability of drug. In this review, we documented the details required to identify the ADRs in patients along with reported banned drugs.
World Health Organization (WHO) defines that adverse drug reactions (ADRs) are noxious and unwanted effects produced by the drug, when it is applied for the ailment of disease or diagnosis (Shukla et al.2012). The most common examples of drugs that produce ADRs include paracetamol and nimesulide (hepatotoxic effects) (Rehan et al.2002).
Before executing any new drug in the market, its clinical trial and safety database are validated for the safety profile of the drug. In various countries, whether developed or developing, the issue of ADRs is accepted to effortlessly, and thus it becomes a prime duty to develop awareness among patients about ADRs.
When a novel drug’s safety is under process, it is being constantly supervised by pharmacovigilance centres for the identification of adverse effects of the drug, if any (Beard1992; Mishra and Kumar2013). According to WHO, pharmacovigilance is a set of practices aiming at the identification, understanding and assessment of risks associate with drugs. Moreover, they take steps to control the adverse effect of drugs. Pharmacovigilance starts from the pre-marketing of new drugs and continues through the post-marketing of drugs (Lazarou et al.1998).
There are a bunch of examples of drugs, which have been detached as well as outlawed from the European market owing to reported adverse effects of drugs. Rosiglitazone holds the first position in the market; other well-known drugs including terfenadine, cisapride, phenylpropanolamine, rofecoxib, cerivastatin, gatifloxacin, cisapride, sibutramine and tegaserod were withdrawn because of their adverse reactions. For every drug in the market, the adverse events, if any, should be inspected in detail, and the facts should be conveyed to the people or public for elucidation of the information (Hampton2005; Lisa et al.2003; Lazarou et al.1998).
In contemplation to supply the news for effective drug use in population, which includes different groups of patients, such as elderly, children and diseased patients, an adequate information regarding drug’s adverse effects is required, which is achieved by a successful pharmacovigilance programmes run on that drug (Gupta and Udupa2011; Santosh and Tragulpiankit2002).
Pharmacovigilance plays several roles such as recognition, observation, assessment and documentation of drug based problems and understanding the factors producing adverse effects (Ravi Shankar et al.2006; Rohilla et al.2012). Here we tried to summarize about ADRs, and how it can be monitored by pharmacovigilance to minimize the adverse effects of drugs. Hence, this review will provide adverse events about ADRs along with the complete information of medication errors.
Proclamations of adverse effects of drug
The USFDA data disclosed that adverse effect of drugs increased almost two times in the endmost decade. It has been noticed that significant sum of patients were pegged out because of fervent adverse effects of drugs. This report has been authenticated in the 10th issue of the Archives of Internal Medicine (Livio et al.2012; Doheny2009; Aeries1995). The number of reports per annum proliferated upto 2.6-fold from 1998 to 2005. In 1998, the numbers of adverse events proclaimed were 34,966, which increased to 89,842 by 2005.
The number of drugs in the market producing ADRs is documented in Table 2.
Documentation of ADRs
The pharmacovigilance curriculum conveyed worldwide to motivate that all suspected drug-related adverse events should be outlined. It takes interests on reports of the following:
Every adverse effect suspected or occurred by new drugs and drugs of current issue.
Documentation of various drugs that caused ADRs, which include death, life-threatening conditions, disability, hospitalization and congenital abnormalities.
The significant adverse reaction of any drug should be notified within seven days. The other facts related to adverse events should be informed within eight days (Bates et al.1995; Classen et al.1997). The ADR form can be collected through any pharmacovigilance centre. The filled ADR form can be submitted to the peripheral pharmacovigilance centre. After reviewing the form, the centre forwards it to the regional centre and after that it is propelled to the zonal centre (Goldman1998; Palaian et al.2006; Ravi Shankar et al.2010). The details are then statistically inspected and forwarded to WHO-Uppsala Monitoring Committee (UMC).
Procedure for reporting ADRs
It is the first duty of any pharmacovigilance centre to report all suspected adverse events of the drug if found. Information regarding ADRs and the type of ADRs that should be reported are tabulated in Table 5.
Monitoring of ADRs
ADR monitoring is spelled out as the practice of continuously monitoring the undesirable effects caused using any drug. Pharmacovigilance plays an imperative impersonation in monitoring ADRs (Hall et al.1995; Hornbuckle et al.1999; Juntti and Neuvoren2002).
It is inherent for pharmaceutical regulators to screen their pharmaceutical products in the market and record if any suspected adverse reactions are identified. ADRs can occur by use of various pharmaceutical products, herbal drugs, cosmetics, medical devices, biological, etc. The introducing of this monitoring procedure intends at warranting that patients receive safe and beneficial medicinal products (Karch and Lasagna1997).
If any of the adverse events are not stated it may result in noxious and serious effects of remedial products. Thus, properly conducting ADR monitoring programmes will help to reduce the harmful effects of therapeutic products (Kessler1993).
Benefits of ADR monitoring
An ADR monitoring and reporting programme can furnish following benefits:
It caters information about quality and safety of pharmaceutical products.
It initiates risk-management plans.
It prevents the predictable adverse effects and helps in measuring ADR incidence.
It instructs health care team, patients, pharmacists and nurses about adverse drug effects and creates awareness regarding ADRs.
ADR monitoring includes different studies for the identification of adverse events
By this method, the unpredictable (bizarre) effects i.e. TYPE-B adverse drug reactions are reported.
This kind of reporting comes through reports of individual doctors when a patient suffers from the particular effect.
Impulsive reporting system
This method is considered as the most efficient method. Mostly, all ADR reporting programmes follow this method. Here, the effects are recorded spontaneously. With this method, both unusual and acute ADRs can be focused on and monitored (Naranjo and Busto1981).
Intensive monitoring studies
Health care members continuously watch the patients and record all the events observed when a drug or different drugs are administered. In this, defined groups of patients are screened to detect ADRs. The main disadvantage of these studies is that the population includes the minimum patients and each patient is studied for the concise period of time. Special investigations can be performed if statistical screening is incorporated in this study method (Naranjo and Busto1981; Nebeker and Barach2008).
In these studies, patients administering similar medicines are identified, and their events are recorded. Major drawbacks of this method are that minimum patients are included and no control group is present for comparison. The contingent examinations are too expensive, and these investigations are difficult to perform on newly marketed drugs (Nissen and Wolski2007).
Case–control studies (Retrospective Studies)
In these studies, patients who have illness or disease due to the use of a drug are investigated to check if they have taken the drug. These patients are then compared with a matched control group that is similar in confounding factors but do not possess the adverse events or illness. This is a useful method in determining whether the drug has caused the adverse event or not. However, by this method, new ADRs cannot be identified (Parthasarathi et al.2007).
Case cohort studies
These studies include both prospective cohort study and retrospective case–control studies; in other words, it is the combination of both the studies (Pearson et al.1994).
In this method, all the records such as prescription records, patient records and hospital records are studied to identify the illness with drugs.
It is a quantitative examination of two or more independent studies to determine the overall effect and to describe reasons in variation of study results (Prosser and Kamysz1990).
Utilitization of resident’s statistics
If a drug-induced event is very frequent and if suspicions arise for them, case–control and experimental cohort studies shall be initiated (Rao2010).
Roles of pharmacovigilance in monitoring ADRs
Many incidents occurred that caused the need of laws and regulations regarding the safe use of drugs. After rofecoxib withdrawal from the European market, the FDA rules on post-market surveillance were criticized and a new system of pharmacovigilance was introduced that provided information on identified risks (Palaian et al.2006; Rawlins and Thompson1981; Yadav2008).
Throughout the early post-marketing period, the product might be used in different groups of people from those used in clinical trials and much larger populations might be exposed in a relatively short time. The post-marketing product is required to develop new information, which can focus on the benefits as well as risks of the product (Arnott et al.2012). Pharmacovigilance produces detailed information of marketed products to ensure their safe use.
The impressive pharmacovigilance planning can reduce the adverse events of drugs in patients. The most important method used in pharmacovigilance is to collect information on a drug when it is in the pre-marketing phase is by conducting a clinical trial. This study design is not optimum to determine the ADRs of the drug. Because in this approach limited numbers of patients participate and it is not necessary that the patients resemble the population in which the drug is to be used (Arora2008; Bahri and Tsintis2005), it becomes impossible to understand the mechanism and consequence of the drug in these groups. Some methods that can be helpful in the detection as well as the prevention of suspected ADRs are listed as follows.
Different study designs are included for proper pharmacovigilance study:
Descriptive studies are conducted to obtain the outcome rate of drug use events in a specific population. These studies include the data of adverse events that occurred in diseased patients. Another factor included is the drug utilization study (Biswas and Biswas2007; Biswas2008). These studies provide data on the specific groups of patients such as children, elderly or patient with renal or hepatic dysfunction. With these data study rates of adverse events can be reported.
Analytical studies are performed to study related outcomes of the exposure to the drug. They can take the form of observational as well as interventional/experimental studies. There are four main types of analytical studies namely ecological, cross-sectional, cohort and case–control (Brewer and Colditz1999).
Observational studies provoke aspects of drug effectiveness in patients during treatment. This is in contrast with experiments, such as randomized controlled trials, where each subject is indiscriminately allocated to a treatment group or a control group (Ciorciaro et al.1998; Jeetu and Anusha2010; Joshi and Sapatnekar2008).
Methods in pharmacovigilance for monitoring of ADR
Spontaneous reports The spontaneous reporting systems were developed after the thalidomide incident. The aim of this spontaneous reporting system is to regulate and control the safety of drugs. This system is applied in the collection of post-marketing information on safety of drugs and identification of safety signals. Consequently, this system is used in the identification of signals of new, rare and serious ADRs of drugs. This system makes it easier for physicians, patients and pharmacists to report suspected ADRs to the pharmacovigilance centre (Herdiero et al.2005; Olsson2008; Rahman et al.2007). The pharmacovigilance centre collects all these reports and informs the stakeholders about the new reported ADRs. By this method, we can monitor all drugs in the market throughout their lifecycles (Ravindra and Vishal2011); (Surendra et al.2010).
Case series The case series are applied in developing a hypothesis between post-marketing drugs and its outcome (Faich1996).
The stimulated reporting system encourages and facilitates health professionals to report ADRs in specific situations. It is very useful in generating adverse events of drugs online (Gerritsen et al.2011). It is effective in generating spontaneous reports of adverse events of drugs identified during the post-marketing phase. This system can assist in minimizing events by linking stimulated reporting with early post-marketing phase (Gupta2010).
Active surveillance includes a pre-organized process to find out more serious adverse events, including the additional efforts to find the adverse reactions. Risk management programme is followed in this process, and more detailed information on individual adverse event reports can be obtained compared with passive surveillance (Panos et al.2004; Harmark and Van Grootheest2008; Surendra et al.2010; Muthiah et al.2012; Lobo et al.2013; Kshirsagar et al.2011).
Comparative observation studies
To test a hypothesis, a study has to be performed. These are the key events to evaluate the adverse events. The study can be conducted using different methods, which can be retrospective and perspective. Major types of these studies are cross-sectional studies, case–control studies and cohort studies (Bates et al.1995). Cross-sectional studies are conducted for ecological analysis. These are helpful in examining the prevalence of any disease at one time point. These studies are helpful to provide information between exposure of the drug and outcome in the ecological analysis.
Case–control study can easily identify the adverse events of drugs. The ADRs are determined by comparing the two distinctive groups. Case–control studies are useful when they are aimed to investigate adverse event in different groups. It is helpful in determining the absolute incidence rate of the adverse events.
Cohort studies provide data that has been collected in a routine fashion. This study can also be used to examine safety issues in specific populations such as children and patients with co-morbid conditions (Gor and Desai2008; Hussein et al.1999).
Earmarked clinical examinations
After pre-approved clinical trials, if sufficient risks are identified, further clinical studies are done to find or evaluate the mechanism of action for the identified adverse reactions. Pharmacokinetic and pharmacodynamic studies are applicable in determining the particular dosing, which can cause enhanced uncertainty of adverse effects in patients. Genetic testing can also be helpful in knowing which group of patients might be at an increased risk of adverse reactions. Children, elderly and patients with renal conditions might metabolize drugs in a different manner compared with patients enrolled or included in clinical trials. By these investigations events of particular interest are focused and used to determine or quantify the magnitude of the risk (Surendra et al.2010).
Thus, all of the above steps are linked with adverse event monitoring studies. Consequently, good safety profile of drug can be established and further suspected adverse events can be minimized and prevented by incorporating the pharmacovigilance methods for adverse drug reactions.
ADRs have a perspective to provoke harmful effects in patients. Health-care workers and pharmacovigilance constrain being more conscious of perceive the ADRs in the patient. In conclusion, this study can be useful for physician to identify the ADRs in patients by applying above mentioned methods.
Aeries N: Consumer reporting of ADRs. WHO Drug Information 1995, 14: 211-215.
Arnott J, Hesselgreaves H, Nunn AJ, Peak M, Pirmohamed M: What can we learn from parents about enhancing participation in Pharmacovigilance? British J Clin Pharmacol 2012, 78(2):312-322.
Arora D: Pharmacovigilance obligations of the pharmaceutical companies in India. Indian J Pharmacol 2008, 40: 13-16.
Bahri P, Tsintis P: Pharmacovigilance–related topics at the level of the International Conference on Harmonisation (ICH). Pharmacoepidemiol Drug Saf 2005, 14: 377-387. 10.1002/pds.1043
Bates DW, Cullen DJ, Laird N: Incidence of adverse drug events and potential adverse drug events. JAMA 1995, 274: 29-34. 10.1001/jama.1995.03530010043033
Beard K: Adverse reactions as a cause of hospital admission in the aged. Indian J Pharmacol 1992, 2: 356-357.
Biswas P: Pharmacovigilance safety matters. Indian J Pharmacol 2008, 7613(40):1-3.
Biswas P, Biswas A: Setting standards for proactive pharmacovigilance in India: The way forward. Indian J Pharmacol 2007, 39: 124-128. 10.4103/0253-7613.33431
Brewer T, Colditz GA: Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 1999, 281: 824-829. 10.1001/jama.281.9.824
Carlo T, Francesco S: Ototoxicity of tobramycin, gentamicin, amikacin and sisomicin. J Antimicrob Chemother 1978, 4: 73-83.
Chyka PA, Erdman AR, Christianson G, Wax PM, Booze LL, Manoguerra AS, Caravati : Salicylate poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol 2007, 45(2):95-131. 10.1080/15563650600907140
Ciorciaro C, Hartmann K, Kuhn M: Differences in the relative incidence of adverse drug reactions in relation to age, an evaluation of the spontaneous reporting system of SANZ. Journal Suisse de medicine 1998, 128: 254-258.
Classen DC, Pestotnik SL, Evans RS: Adverse drug events in hospitalized patients. JAMA 1997, 277(4):301-306. 10.1001/jama.1997.03540280039031
Cole M, Proctor GB, Trigoboff E: Adverse Drug Reaction Review: Evaluation of Concomitant Medications Effecting Blood Dyscrasias Associated with Clozapine. American Society of Health-System Pharmacists, Las Vegas December 6-10; 2009.
Delini SA, Mikkelsen H, Angst J: Therapeutic efficacy of antidepressants in agitated anxious depression–a meta-analysis of moclobemide studies. J Affect Disord 2007, 35(2):21-30.
Doheny K: Reports of adverse drug effects up. Web MD Health News 2009, 6: 1-2.
Douketis JD, Crowther M, Wells PS: A review on propofol and its drug and food interactions. Arch Intern Med 2007, 45(10):167-176.
Faich GA: U.S. adverse drug reaction surveillance. Pharmacoepidemiol Drug Saf 1996, 5(6):393-398. 10.1002/(SICI)1099-1557(199611)5:6<393::AID-PDS235>3.0.CO;2-H
FDA: Early Communication about Safety of Lantus (insulin glargine). US Food and Drug Adminstration, Silver Spring, MD; 2009.
Fu H, Darroch JE, Henshaw SK, Kolb E: Measuring the extent of abortion underreporting in the 1995. Fam Plann Perspect 1998, 30: 128-133. 138 10.2307/2991627
Gaudreault P, Temple AR, Lovejoy FH: The relative severity of acute versus chronic salicylate poisoning in children: a clinical comparison. Pediatrics 1982, 70(4):566-569.
Gerritsen R, Faddegon H, Dijkers F, VanGrootheest K, Van Puijenbroek E: Effectiveness of pharmacovigilance training of general practitioners: a retrospective cohort study in the Netherlands comparing two methods. Drug Saf 2011, 34: 755-762. 10.2165/11592800-000000000-00000
Goldman SA: Limitations and strengths of spontaneous reports data. Clinical Therapeutic 1998, 4: 40-44.
Gor AP, Desai SV: Adverse drug reaction in the in patients of medicine department of a rural tertiary care teaching hospital and influence of pharmacovigilance in reporting ADR. Indian J Pharmacol 2008, 40(1):37-40. 10.4103/0253-7613.40488
Gupta Y: Ensuring patient safety- launching the new pharmacovigilance programme of india. Pharma Times 2010, 42(8):234-289.
Gupta P, Udupa A: Adverse drug Reaction Reporting and pharmacovigilance: knowledge, attitudes and perceptions amongst resident doctors. J Pharm Sci Res 2011, 1459(2):1064-1069.
Hall M, Mc Cormack P, Arthurs N, Feely J: The spontaneous reporting of ADRs by nurses. British J ClinPharmacol 1995, 3: 173-175.
Halpern GM: COX-2 inhibitors: a story of greed, deception and death. Inflammo Pharmacology 2005, 13(4):419-425. 10.1163/156856005774415574
Hampton T: Experts point to lessons learned from controversy over rofecoxib safety. JAMA 2005, 293: 413-414.
Harmark L, Van Grootheest AC: Pharmacovigilance: methods, recent developments and future perspective. European J ClinPharmacol 2008, 64(6):743-752.
Haupt M, Jeste D: Mortality in elderly dementia patients treated with risperidone. J ClinPsychopharmacol 2006, 26(6):566-570.
He Q, Luo X, Jin W, Huang Y, Reddy MV: Celecoxib and a novel COX-2 inhibitor ON09310 up regulate death receptor 5 expression via GADD153/CHOP. Inflammo Pharmacology 2005, 13(4):419-425. 10.1163/156856005774415574
Herdiero MT, Figueiras A, Polonia J: Physians attitudes and adverse drug reaction reporting: a case control study in Portugal. Drug Saf 2005, 28(9):825-833. 10.2165/00002018-200528090-00007
Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS: Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005, 165(10):1095-1106. 10.1001/archinte.165.10.1095
Holford NH: Clinical pharmacokinetics and pharmacodynamics of warfarin understanding the dose-effect relationship. Clin Pharmacokinet 1986, 11(6):483-504. 10.2165/00003088-198611060-00005
Hornbuckle K, Wu HH, Fung MC: Evaluation of spontaneous adverse event reports by primary reporter - a 15-year review (1983 to 1997). Drug Inf J 1999, 33: 1117-1124.
Huismen C, Ferreira CG, Broker LE: Paclitaxel triggers cell death primarily via caspase-independent routes in the non-small cell lung cancer cell line. Clin cancer Res 2002, 8(2):596-606.
Hussein G, Bleidt B, Belding B: Recognition evaluation and reporting of adverse drug reactions. Clin Res Regul Aff 1999, 16(3):91-107. 10.3109/10601339909007064
Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y, Handa H: Identification of a primary target of thalidomide teratogenicity. Science 2010, 327(5971):1345-1350. 10.1126/science.1177319
Jankovic J, beach J: Long term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997, 48(2):358-362. 10.1212/WNL.48.2.358
Jeetu G, Anusha G: Pharmacovigilance: a worldwide master key for drug safety monitoring. Journal Young Pharm 2010, 2(3):315-316. 10.4103/0975-1483.66802
Joshi SR, Sapatnekar SM: The importance of pharmacovigilance. Geneva: World Health Organization, Pharmacovigilance in India: how safe are the new drugs? How sure are we? J Assoc Physicians Ind 2008, 56(8):933-934.
Juntti PL, Neuvoren PJ: Drug related deaths in a university central hospital. Eur J ClinPharmacol 2002, 58: 479-482.
Karch FE, Lasagna L: Towards the operational identification of adverse drug reactions. Clin Pharmacol Ther 1997, 21: 247-254.
Kessler DA: Introducing Med Watch, using FDA form 3500, a new approach to reporting medication and device adverse effects and product problems. JAMA 1993, 269: 2765-2778. 10.1001/jama.1993.03500210065033
Krumholz HM, Ross JS, Presler AH: What have we learnt from Vioxx? Br Med J 2007, 334: 120-123. 10.1136/bmj.39024.487720.68
Kshirsagar N, Ferner R, Figueroa BA, Ghalib H, Lazdin J: Pharmacovigilance methods in public health programmes: the example of miltefosine and visceral leishmaniasis. Trans R Soc Trop Med Hyg 2011, 105: 61-67. 10.1016/j.trstmh.2010.11.004
Kung HC, Hoyert DL, Xu JQ, Murphy SL: Increase in poisoning and methadone related effects; National Center for Health Statistics. Natl Vital Stat Rep 2008, 56(10):8-15.
Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients-a meta-analysis of prospective studies. JAMA 1998, 2: 1200-1205.
Lisa A, Ladewski SM, Belknap JR, Nebeker OS: Dissemination of information on potentially fatal adverse drug reactions of drugs from 2000 to 2002: first results from the research on adverse drug events and reports project. J ClinOncol 2003, 21(20):3859-3866. 10.1200/JCO.2003.04.537
Livio F, Renard D, Buclin T: Pharmacovigilance, a review. Med Suisse 2012, 8: 116-119.
Lobo A, Germana M, Gerley J: Adverse drug reaction monitoring; support for pharmacovigilance at a tertiary care hospital in northern Brazil. BMC Pharmacol Toxicol 2013, 78(3):1-7.
Marx J: Rosen’s Emergency Medicine: Concepts and Clinical Practice. Mosby Inc Mosby/Elsevier, Maryland Heights, Missouri; 2006:2242.
Michael S, Ma L: Fluoxetine and suicide rates suicide and the economy. J Pub Med 2006, 3(11):501-503.
Minino AM, Anderson RN, Fingerhut LA, Boudreault MA, Warner M: Deaths: injuries. Natl Vital Stat Rep 2002, 54(10):1-20.
Mishra H, Kumar V: Pharmacovigilance: current scenario in a tertiary care teaching Medical College in North India. Journal Pharmacovigilance 2013, 1(2):1-4.
Mohammed A: Analysis of multiple risks involving the use of IV fentanyl. Patient Safe Advis 2012, 9(4):122-129.
Moore N: The role of the clinical pharmacologist in the management of ADRs. Drug Saf 2001, 24(1):1-7. 10.2165/00002018-200124010-00001
Murphy BM, Frigo LC: Development implementation and results of a successful ultidisciplinary adverse drug reaction reporting Program in a University Teaching Hospital. Hospital Pharm 1993, 28: 1199-1240.
Muthiah NS, Elumalai M, Murali NP: HazraRamsundar: pharmacovigilance: a tool for health safety- review article. Indian J Multidiscip Dent 2012, 2(1):374-376.
Naranjo CA, Busto U: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981, 30: 239-245. 10.1038/clpt.1981.154
Nebeker JR, Barach P: Clarifying adverse drug events, a clinicians view. Ann Intern Med 2008, 12: 87-112.
Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356: 2457-2471. 10.1056/NEJMoa072761
Olsson S: Pharmacovigilance training with focus on India. Ind J Pharmacol 2008, 40(7):28-30.
Orlando M, Perkins CL: Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Clin cancer Res 2002, 8(2):596-606.
Palaian S, Mishra P, Shankar PR, Dubey AK, Bista D, Almeida R: Safety monitoring of drugs- where do we stand? Kathmandu Univ Med J 2006, 4(13):119-120.
Panos T, Sintis P, La Mache E: CIOMS and ICH initiatives in pharmacovigilance and risk management overview and implications European agency for the evaluation of medicinal products. London, United Kingdom Drug Safety 2004, 27(8):509-517.
Parthasarathi G, Karin Nyfort H, Nahata MC: Adverse Drug Reactions. A Textbook of Clinical Pharmacy Practice Essentials Concepts and Skills, vol 76. University Press, Hyderabad; 2007:84-102.
Pasero C: Fentanyl for acute pain management. J Perianesth Nurs 2005, 20(4):279-284. 10.1016/j.jopan.2005.03.007
Pearson TF, Pittman D, Longley JM, Grapes T, Vigliotti DJ, Mullis SR: Factors associated with preventable adverse drug reactions. Am J Hosp Pharm 1994, 51: 2268-2271.
Peng PW, Sandler AN: A review of the use of fentanyl analgesia in the management of acute pain in adults. Anesthesiology 1999, 90(2):576-599. 10.1097/00000542-199902000-00034
Prommer E: The role of fentanyl in cancer-related pain. J Palliat Med 2009, 12(10):947-954. 10.1089/jpm.2009.0051
Prosser TR, Kamysz PL: Multidisciplinary adverse drug reaction surveillance program. American J Hosp Pharm 1990, 47: 1334-1339.
Purdue Pharma L.P. Stamford, CT: 06901-3431 2010 U.S. Patent Numbers 5,508,042; 6,488,963; 7,129,248; 7,674,799; 7,674,800 and 7,683,072. 2009.
Rahman SZ, Khan RA, Gupta V, Uddin M: Pharmacoenvironmentology - a component of pharmacovigilance. Environmental Health 2007, 56(20):38-42.
Rao HP: Reporting of adverse drug reactions by consumers: rationale and potential. Pharmbit. Am J Hosp Pharm 2010, 22(20):110.
Ravi Shankar P, Subish P, Mishra P, Dubey AK: Teaching pharmacovigilance to medical students and doctors. Indian J Pharmacol 2006, 38(5):316-319. 10.4103/0253-7613.27698
Ravi Shankar P, Subish P, Mishra P, Dubey AK: Teaching Pharmacovigilance to Medical students and doctors. Educational Forum 2010, 38(5):37-379.
Ravindra A, Vishal B: Pharmacovigilance: an overview. Int J Res Pharmacy Chemistry 2011, 1(40):968-969.
Rawlins MD, Thompson JW: Mechanisms of Adverse Drug Reactions. In Textbook of Adverse Drug Reactions. 4th edition. Oxford: Oxford University press; 1981.
Rehan HS, Vasudev K, Tripathi CD: Adverse drug reaction monitoring: knowledge, attitude and practices of medical students and prescribers. Natl Med J India 2002, 15(1):24-25.
Rishi RK, Patel RK, Bhandari A: Opinion of physicians towards adverse drug reactions reporting results of pilot study. J Commun Nutr Health 2012, 1(1):25.
Rohilla A, Singh N, Kumar V, Sharma MK, Dahiya A, Kushnoor A: Pharmacovigilance: needs and objectives- review article. J Adv Pharm Technol Res 2012, 2(4):201-205.
Santosh KC, Tragulpiankit P: Pharmacovigilance: an overeview. Department of Pharmacy, Faculty of Pharmacy Mahidol University. Journal of Pharmaceutical Sciences 2002, 21: 23-146.
Schluter G: Ciprofloxacin: toxicological evaluation of additional safety data. Am J Med 1989, 87(5):99-106.
Schonthal AH, Chen TC, Hofman FM, Louie SG, Petasis NA: Celecoxib analogs that lack. COX-2 inhibitory function: preclinical development of novel anticancer drugs. Expert Opin Investig Drugs 2003, 17(2):197-208.
Shukla SS, Gidwani B, Pandey R, Rao SP, Singh V, Vyas : A importance of pharmacovigilance in Indian pharmaceutical industry – review article. Asian Pharma Online 2012, 5: 2231-5659.
Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn : Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. American J 2004, 109: 2068-2073.
Surendra S, Dang A, Rataboli P: Pharmacovigilance and Pharmaco epidemiology. Indian J Pharm Sci 2010, 72(1):96-102.
Thisted B, Krantz T, Stroom J, Sorensen M: Acute salicylate self-poisoning in 177 consecutive patients treated in ICU. Actaanaesthesiologica Scandinavica 1986, 31(4):312-316.
Yadav S: Status of adverse drug reaction monitoring and pharmacovigilance in selected countries. Indian J Pharmacol 2008, 40: 4-9.
The authors declare that they have no competing interests.
RKS and RY carried out literature review and draft the manuscript. PP, AR and SC participated in collection of data and arranged in tabular form. All authors read and approved the final manuscript.
About this article
Cite this article
Sahu, R.K., Yadav, R., Prasad, P. et al. Adverse drug reactions monitoring: prospects and impending challenges for pharmacovigilance. SpringerPlus 3, 695 (2014). https://doi.org/10.1186/2193-1801-3-695
- Adverse drug reactions
- Clinical trial